Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Latest From Brian Yang

Setbacks For China Pharma As Firms Hit With Antitrust Fine, Clinical Setback

One of China's largest domestic pharma conglomerates has been fined more than $100m for price-fixing and other monopoly acts, while another firm has seen a major Phase III setback for its global launch hope.

China Commercial

Sinovac Real-World Data In Brazil Shed Fresh Light On China COVID Vaccine Efficacy Debate

Sinovac’s COVID-19 vaccine has an efficacy rate of 50% in one hard-hit region of Brazil, a study finds, which could fuel fresh doubts over the efficacy of Chinese vaccines and raise the urgency to change current vaccination strategy.

Real-World Evidence Coronavirus COVID-19

Sinovac Real World Data Shed Fresh Light On China COVID Vaccine Efficacy Debate

New real world data for Sinovac’s COVID-19 vaccine from hard-hit Brazil could fuel fresh doubts over the efficacy of Chinese vaccines, but also raise the urgency to change current vaccination strategy.

Coronavirus COVID-19 Vaccines

Alibaba's Unprecedented $2.8bn Fine Could Signal Start Of Antitrust Wave In China

China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions. 

E-Commerce Enforcement

China COVID-19 Vaccines Efficacy Inadequate? Hot Debate, Variant Worries Swirl

China's regulators and spin doctors rush to remedy a comment from the nation’s top infectious disease official about the “not high” protection rate for its COVID-19 vaccines, amid debate over speedy development using mature technologies and doubts over protection in seniors. A slow roll-out is already presenting challenges to meeting an official 40% target.

China Coronavirus COVID-19

Pharma Not Immune From Coming Antitrust Wave In China

China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. While the pharma sector remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.

China Legal Issues
See All
UsernamePublicRestriction

Register